Superworth

Rallybio EPS RLYB

Diluted earnings per share by quarter and over the last twelve months, from 2020.

Last 12 months, to Sep 30, 2026
$4.56
Latest quarter, Q3 FY26
−$0.48
−117% on a year earlier
Fiscal year 2025
−$1.64

Rallybio's earnings per share was $4.56 over the twelve months to Sep 30, 2026.

In its latest quarter, Q3 FY26, it was −$0.48, down 117% on the same quarter a year before.

Earnings per share over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearEPSChange
FY2025−$1.64n/a
FY2024−$10.80n/a
FY2023−$14.72n/a
FY2022−$16.88n/a
FY2021−$14.96n/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedEPSOn a year earlierLast 12 months
Q3 FY26−$0.48−117%$4.56
Q2 FY26$7.53n/a$7.88
Q1 FY26−$1.46n/a−$1.41
Q4 FY25−$1.03n/a−$1.64
Q3 FY25$2.84n/a−$2.61
Q2 FY25−$1.76n/a−$7.53
Q1 FY25−$1.69n/a−$8.73
Q4 FY24−$2.00n/a−$10.80
Q3 FY24−$2.08n/a−$12.80
Q2 FY24−$2.96n/a−$14.32
Q1 FY24−$3.76n/a−$15.04
Q4 FY23−$4.00n/a−$14.72

Against its peers

Companies in Drug Manufacturers - General nearest Rallybio's size, closest first, today.

CompanyEPS, 12 monthsGrowth
RLYBRallybio$4.56
LFVNLifevantage$0.40−46% a year
SPROSpero Therapeutics$0.11
ATNMActinium Pharmaceuticals$0.36
NATRNatures Sunshine Products$1.01+36% a year
CRMDCorMedix$2.13+184% a year
ARVNArvinas$0.16
PBYIPuma Biotechnology$0.52−47% a year
IRWDIronwood Pharmaceuticals$0.77
ZVRAZevra Therapeutics$0.93
COLLCollegium Pharmaceutical$1.24+19% a year
Peer median$0.65

What the EPS figure tells you

Net income divided by diluted shares. The denominator of PE.

One-off charges and gains swing it. The TTM view smooths a single odd quarter.

More on Rallybio

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.